Posted on Dec 11th 2018
Learn about the hottest new small molecules in cancer research today including STING reagents and other immunomodulators!
Multiple cellular pathways can lead to acquired resistance to ALK inhibitors. A common pathway is activation of alternate kinase pathways, including EGFR, KIT, SRC, and IGF1R to maintain activation of downstream ERK and/or PI3K-AKT signaling. Addition of inhibitors to these pathways is a viable response, but not optimal due to the presence of multiple alternatives. Dardaei [...]
Researchers at the Salk Institute, the University of California, and the University of Texas have identified a potential new class of cancer therapeutics. REV-ERBs are nuclear hormone receptors that are critical components of the circadian clock, the body's mechanism for establishing daily rhythms in cellular proliferation, metabolism, and other essential processes. Dysregulation of this system is [...]